The company specializes in creating bio-medical therapeutics for orphan metabolic diseases, with a particular focus on central nervous system diseases and disorders of neurotransmitter degradation and synthesis. Through its innovative therapeutics, Censa Pharmaceuticals aims to help patients recover from debilitating diseases that would otherwise have no treatment options. The company's early-stage programs show great promise in treating (ultra) orphan CNS disorders, offering hope to patients and their families.